Balancing Biopharma’s Supply Chain Priorities

Scroll Down

With intense pressure placed upon the biopharmaceutical industry to rapidly develop and produce COVID-19 vaccines, diagnostics and therapeutics, it is imperative that CDMOs adapt to ensure they can deal with the increased demand and existing commitments.

In this roundtable, Bill Vincent, Genezen Founder, provides insight into how COVID-19 has accelerated demand for clinical products and outlines how CDMOs are dealing with this pressure despite constraints on the supply of raw materials as well as manufacturing capacity issues.

Read the full article here.

 

You may also be interested in...

LVV Approaches to Pseudotyping and Plasmid…

As cell and gene therapies (C>s) continue to provide unprecedented advancements...

Read more

Genezen Announces the Appointment of Steven…

BOSTON, MA and FISHERS, IN. – March 13, 2023 – Genezen,...

Read more

Omar Lamm on Developments in Pharma…

An interview with Omar Lamm discussing his career in pharma, where...

Read more

Understanding the requirements of viral vector…

Analytical method development, qualification, and validation are an integral part of...

Read more